What question did this study set out to answer?

The research aims to identify key regulatory genes and prognostic markers in gastric cancer to aid personalized treatment.

May 1, 2026

Integrative systems biology and drug repurposing reveal key regulatory hubs and a prognostic signature in gastric cancer.

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrates key regulatory genes and drug candidates in gastric cancer, suggesting new therapeutic strategies.

The research aims to identify key regulatory genes and prognostic markers in gastric cancer to aid personalized treatment.
Performed integrative systems biology analysis on microarray data (GSE146996) of tumor and normal gastric tissues.
Constructed a protein-protein interaction network and prioritized hub genes using CytoHubba.
Developed a prognostic signature using RNA-seq and survival data from the TCGA-STAD cohort.
Identified 16,304 differentially expressed genes, revealing FN1 and SRSF7 as significantly associated with overall survival.
Developed a two-gene prognostic model showing modest stratification with log-rank p = 0.047.
Docking analysis highlighted high-affinity compound-protein interactions for potential therapeutic candidates.

Akhavan et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark